The state of Utah currently has 7 active clinical trials seeking participants for Healthy research studies. These trials are conducted in various cities, including Salt Lake City, Murray, Ogden and West Jordan.
Single and Multiple Ascending Dose Study and Food Effect Study for AG181
Recruiting
The primary purpose of this study is to assess the safety and tolerability of AG-181 in healthy participants after oral administration of single ascending dose (SAD) of AG-181 in Part 1 and multiple ascending dose (MAD) in Part 2 along with the effect of food on the pharmacokinetics (PK) of single oral doses of AG-181 in healthy participants in Part 3.
Gender:
ALL
Ages:
Between 18 years and 55 years
Trial Updated:
01/23/2025
Locations: ICON 1255 East 3900 South, Salt Lake City, Utah
Conditions: Healthy Volunteers
A First-In-Human Study of LY3985297 in Healthy Participants
Recruiting
The main purpose of this study is to see if LY3985297, the study drug, is safe and well-tolerated when given as a single dose or as multiple doses either through an intravenous (into a vein) or a subcutaneous (under the skin) injection in healthy participants. Study will also evaluate how much of the study drug LY3985297 gets into the blood stream and how long it takes the body to remove it. The study is conducted in two parts (part A and B), each part has a separate treatment cohort. The stud... Read More
Gender:
ALL
Ages:
Between 18 years and 64 years
Trial Updated:
01/03/2025
Locations: ICON, Salt Lake City, Utah
Conditions: Healthy
A Study to Assess the Concentration of Rozanolixizumab in the Breast Milk of Healthy Lactating Women
Recruiting
The purpose of the study is to assess the concentration of rozanolixizumab in mature breast milk of healthy study participants following administration of a single dose of rozanolixizumab
Gender:
FEMALE
Ages:
18 years and above
Trial Updated:
12/11/2024
Locations: UP0141 1, Salt Lake City, Utah
Conditions: Healthy Participants
A Study to Characterize Single and Repeat Dose Pharmacokinetics of Tebipenem-Pivoxil-Hydrobromide (TBP-PI-HBr) and Its Major Metabolite (SPR1349) in Healthy Participants
Recruiting
The main purpose of the study is to characterize the systemic pharmacokinetic (PK) parameters (plasma, whole blood) of tebipenem (TBP) pharmacologically active moiety of tebipenem-pivoxil-hydrobromide (TBP-PI-HBr) and its urinary excretion at different dose levels in healthy participants. The study also aims to assess the plasma and urine PK parameters of SPR1349, a major metabolite of TBP.
Gender:
ALL
Ages:
Between 18 years and 55 years
Trial Updated:
12/06/2024
Locations: Medical Facility, Salt Lake City, Salt Lake City, Utah
Conditions: Healthy Participants
A Study to Evaluate the PK and PD of IM or SQ Injections of Levonorgestrel Butanoate (LB) for Female Contraception
Recruiting
This is a Phase I multicenter, open-label, dose-ranging, three-dose PK and PD study of injectable LB administered as an IM or SQ injection at 40 mg, and subsequently at 50mg SQ and then 60 mg SQ depending on the preliminary pharmacokinetic and pharmacodynamic results obtained with 40 mg dosing.
Gender:
Female
Ages:
Between 18 years and 40 years
Trial Updated:
08/11/2023
Locations: University of Utah, Salt Lake City, Utah
Conditions: Healthy Women, Female Contraception
Establish ProLung Test Measurement Collection Protocol for Future Studies.
Recruiting
The purpose of this Study is to identify and test different data collection methods to determine which approaches improve the ProLung Testing procedure. Once this Study is complete, the Sponsor plans to evaluate these improvements in future follow up Validation studies that will assess device accuracy using the new measurement collection methods.
Gender:
All
Ages:
18 years and above
Trial Updated:
10/21/2022
Locations: Ogden Regional Medical Center, Ogden, Utah +1 locations
Conditions: Cancer , Healthy
Precision Genomics Medicine Biobank
Recruiting
The immediate goal of this study is to collect biological samples (i.e., tissue and/or fluid), clinical information, and laboratory data from disease and non-disease subjects seen at Intermountain Healthcare affiliated facilities. The long-term goal is to annotate tissue and/or fluid biomarker data to clinical information and laboratory data for the purpose of improving health care delivery and prognostic potential.
Gender:
All
Ages:
18 years and above
Trial Updated:
04/18/2022
Locations: Intermountain Healthcare, Murray, Utah
Conditions: Any Disease Condition and Reportedly-healthy Subjects